Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00024310
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 45
- Registration Number
- NCT00009802
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy in Treating Patients With Solid Tumors
- Conditions
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 65
- Registration Number
- NCT00062062
- Locations
- 🇺🇸
Promedica Cancer Center at Flower Hospital, Sylvania, Ohio, United States
🇺🇸Medical College of Ohio Cancer Institute, Toledo, Ohio, United States
🇺🇸St. Vincent Mercy Medical Center, Toledo, Ohio, United States
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00062179
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 37
- Registration Number
- NCT00062010
- Locations
- 🇺🇸
CCOP - Columbus, Columbus, Ohio, United States
🇺🇸Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸HealthEast Cancer Care at St. Joseph's Hospital, Saint Paul, Minnesota, United States
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00006484
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00008021
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
- Conditions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006377
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
- Conditions
- First Posted Date
- 2003-05-16
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT00005078
- Locations
- 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.